Cover Image
市場調查報告書

P2X嘌呤受體3 (P2RX3) :開發中產品分析

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364861
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
P2X嘌呤受體3 (P2RX3) :開發中產品分析 P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 59 Pages
簡介

本報告提供以P2X嘌呤受體3 (P2RX3) 為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

P2X嘌呤受體3 (P2RX3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Afferent Pharmaceuticals, Inc.
  • Asana BioSciences, LLC
  • Integral Molecular, Inc.
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc.
  • 鹽野義製藥

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0155TDB

Summary

Global Markets Direct's, 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016', provides in depth analysis on P2X Purinoceptor 3 (P2RX3) targeted pipeline therapeutics.

The report provides comprehensive information on the P2X Purinoceptor 3 (P2RX3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
  • The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • P2X Purinoceptor 3 (P2RX3) Overview
  • Therapeutics Development
    • P2X Purinoceptor 3 (P2RX3) - Products under Development by Stage of Development
    • P2X Purinoceptor 3 (P2RX3) - Products under Development by Therapy Area
    • P2X Purinoceptor 3 (P2RX3) - Products under Development by Indication
  • P2X Purinoceptor 3 (P2RX3) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • P2X Purinoceptor 3 (P2RX3) - Products under Development by Companies
  • P2X Purinoceptor 3 (P2RX3) - Products under Development by Universities/Institutes
  • P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
    • Afferent Pharmaceuticals, Inc.
    • Asana BioSciences, LLC
    • Integral Molecular, Inc.
    • Neurim Pharmaceuticals Ltd
    • Pfizer Inc.
    • Shionogi & Co., Ltd.
  • P2X Purinoceptor 3 (P2RX3) - Drug Profiles
    • AF-130 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AF-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-300 Backups - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piromelatine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • P2X Purinoceptor 3 (P2RX3) - Dormant Projects
  • P2X Purinoceptor 3 (P2RX3) - Discontinued Products
  • P2X Purinoceptor 3 (P2RX3) - Featured News & Press Releases
    • May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference
    • May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
    • Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
    • Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference
    • Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial
    • Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients
    • Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
    • Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome
    • Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
    • Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219
    • Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia
    • Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11
    • Aug 25, 2010: Afferent Reports Data Supporting Potential Utility Of P2X3 Antagonists In Lowering Bladder Reflexes
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Afferent Pharmaceuticals, Inc., H1 2016
  • Pipeline by Asana BioSciences, LLC, H1 2016
  • Pipeline by Integral Molecular, Inc., H1 2016
  • Pipeline by Neurim Pharmaceuticals Ltd, H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Pipeline by Shionogi & Co., Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top